[1]
|
Hill QA. Autoimmune hemolytic anemia[J]. Hematology, 2015, 20: 553-554. doi: 10.1179/1024533215Z.000000000401 |
[2]
|
Penalver FJ, Alvarez-Larran A, Diez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia[J]. Ann Hematol, 2010, 89: 1073-1080. doi: 10.1007/s00277-010-0997-y |
[3]
|
Ratnasingam S, Walker PA, Tran H, et al. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases[J]. Blood Adv, 2016, 1: 31-35. doi: 10.1182/bloodadvances.2016001412 |
[4]
|
Muhsen IN, Alahmari A, Alnahedh M, et al. Bortezomib for immune thrombocytopenia and autoimmune hemolytic anemia[J]. Hematol Oncol Stem Cell Ther, 2019, S1658-3876: 30051-30052. http://www.sciencedirect.com/science/article/pii/S1658387619300512 |
[5]
|
Chen M, Zhuang JL, Yang C, et al. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia[J]. Ann Hematol, 2020, 99: 1141-1143. doi: 10.1007/s00277-020-03976-w |
[6]
|
Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features[J]. Blood, 2000, 95: 2786-2792. doi: 10.1182/blood.V95.9.2786.009k30_2786_2792 |
[7]
|
郑雪娜, 魏锦, 谭竞. 慢性淋巴细胞白血病相关性自身免疫性溶血性贫血的发病机制[J]. 中国临床医学, 2011, 18: 132-135. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201101046.htm
Zheng XN, Wei J, Tan J. Mechanisms about chronic lymphocytic leukemia-associated autoimmune hemolytic anemia[J]. Zhongguo Lin Chuang Yi Xue, 2011, 18: 132-135. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201101046.htm |
[8]
|
Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance[J]. Blood, 2010, 116: 4771-4776. http://europepmc.org/abstract/MED/20736453 |
[9]
|
Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma[J]. Br J Haematol, 2008, 141: 615-621. doi: 10.1111/j.1365-2141.2008.07086.x |
[10]
|
Jaime-Pérez JC, Aguilar-Calderón PE, Salazar-Cavazos L, et al. Evans syndrome: clinical perspectives, biological insights and treatment modalities[J]. J Blood Med, 2018, 9: 171-184. doi: 10.2147/JBM.S176144 |
[11]
|
Hauswirth AW, Skrabs C, Schützinger C, et al. Autoim-mune hemolytic anemias, Evans' syndrome, and pure red cell aplasia in non-Hodgkin lymphomas[J]. Leuk Lymphoma, 2007, 48: 1139-1149. doi: 10.1080/10428190701385173 |